Literature DB >> 24470139

Development of anticancer drugs based on the hallmarks of tumor cells.

Natalia Bailón-Moscoso1, Juan Carlos Romero-Benavides, Patricia Ostrosky-Wegman.   

Abstract

Cancer remains a public health problem with a high unmet medical demand. However, in recent decades, the knowledge of several functional molecular and biological traits that distinguish tumor cells from normal cells, known as the hallmarks of cancer as described by Hannahan and Weinberg, has led to new and modern therapeutic approaches against this disease. Most cancer drugs are deliberately developed for specific molecular targets that involve these hallmarks. In this review, we address the currently available cancer drugs and development of new drugs from the perspective of their interaction with these hallmarks as well as the pathways and mechanisms involved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24470139     DOI: 10.1007/s13277-014-1649-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  181 in total

1.  The two faces of autophagy and the pathological underestimation of DCIS.

Authors:  Ke-Da Yu; Zhi-Ming Shao
Journal:  Nat Rev Cancer       Date:  2011-07-22       Impact factor: 60.716

Review 2.  Antivascular therapy of cancer: DMXAA.

Authors:  Bruce C Baguley
Journal:  Lancet Oncol       Date:  2003-03       Impact factor: 41.316

Review 3.  Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration.

Authors:  Da-Qing Yang; Marie-Jo Halaby; Yan Li; Jody C Hibma; Paul Burn
Journal:  Drug Discov Today       Date:  2011-02-15       Impact factor: 7.851

Review 4.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

Review 5.  Interleukin-6 signaling pathway in targeted therapy for cancer.

Authors:  Yuqi Guo; Feng Xu; TianJian Lu; Zhenfeng Duan; Zhan Zhang
Journal:  Cancer Treat Rev       Date:  2012-05-29       Impact factor: 12.111

Review 6.  Autophagic pathways as new targets for cancer drug development.

Authors:  Bo Liu; Yan Cheng; Qian Liu; Jin-ku Bao; Jin-Ming Yang
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 7.  Helminths in human carcinogenesis.

Authors:  Bernard Fried; Aditya Reddy; David Mayer
Journal:  Cancer Lett       Date:  2010-07-27       Impact factor: 8.679

Review 8.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

Review 9.  Aurora kinase inhibitors.

Authors:  J J E M Kitzen; M J A de Jonge; J Verweij
Journal:  Crit Rev Oncol Hematol       Date:  2009-04-14       Impact factor: 6.312

Review 10.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

View more
  8 in total

1.  A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.

Authors:  Gaoxin Lei; Menglong Xu; Zhipan Xu; Lili Gu; Chenchen Lu; Zhengli Bai; Yue Wang; Yongbo Zhang; Huajing Hu; Yiwei Jiang; Wenfeng Zhao; Shuhua Tan
Journal:  Int J Mol Sci       Date:  2017-09-27       Impact factor: 5.923

2.  Cytotoxic, antioxidative, genotoxic and antigenotoxic effects of Horchata, beverage of South Ecuador.

Authors:  Natalia Bailon-Moscoso; Fani Tinitana; Ruth Martínez-Espinosa; Andrea Jaramillo-Velez; Alejandra Palacio-Arpi; Jessica Aguilar-Hernandez; Juan Carlos Romero-Benavides
Journal:  BMC Complement Altern Med       Date:  2017-12-19       Impact factor: 3.659

Review 3.  Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression.

Authors:  Edward A Ratovitski
Journal:  Curr Genomics       Date:  2017-04       Impact factor: 2.236

Review 4.  Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.

Authors:  Natalia Bailon-Moscoso; Gabriela Cevallos-Solorzano; Juan Carlos Romero-Benavides; Maria Isabel Ramirez Orellana
Journal:  Curr Genomics       Date:  2017-04       Impact factor: 2.236

5.  Synthesis and Cytotoxic Analysis of Novel Myrtenyl Grafted Pseudo-Peptides Revealed Potential Candidates for Anticancer Therapy.

Authors:  Odette Concepción; Julio Belmar; Alexander F de la Torre; Francisco M Muñiz; Mariano W Pertino; Barbara Alarcón; Valeska Ormazabal; Estefania Nova-Lamperti; Felipe A Zúñiga; Claudio A Jiménez
Journal:  Molecules       Date:  2020-04-21       Impact factor: 4.411

6.  Systems Drug Discovery for Diffuse Large B Cell Lymphoma Based on Pathogenic Molecular Mechanism via Big Data Mining and Deep Learning Method.

Authors:  Shan-Ju Yeh; Tsun-Yung Yeh; Bor-Sen Chen
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

7.  Phytometabolite Dehydroleucodine Induces Cell Cycle Arrest, Apoptosis, and DNA Damage in Human Astrocytoma Cells through p73/p53 Regulation.

Authors:  Natalia Bailon-Moscoso; Gabriela González-Arévalo; Gabriela Velásquez-Rojas; Omar Malagon; Giovanni Vidari; Alejandro Zentella-Dehesa; Edward A Ratovitski; Patricia Ostrosky-Wegman
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

8.  Predicting chemotherapeutic drug combinations through gene network profiling.

Authors:  Thi Thuy Trang Nguyen; Jacqueline Kia Kee Chua; Kwi Shan Seah; Seok Hwee Koo; Jie Yin Yee; Eugene Guorong Yang; Kim Kiat Lim; Shermaine Yu Wen Pang; Audrey Yuen; Louxin Zhang; Wee Han Ang; Brian Dymock; Edmund Jon Deoon Lee; Ee Sin Chen
Journal:  Sci Rep       Date:  2016-01-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.